Table 3 Characteristics associated with long-term mortality in patients with acute ischemic stroke (n = 892). Median follow-up was 80 months (IQR 32–85)
Bivariate analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
Survival n = 509 | Death n = 383 | p value | Probability death HR (95 % CI) | p value | |
Age in years; median (IQR) | 65.0 (56.5–73.0) | 75.0 (68.0–83.0) | <0.001 | 1.70 (1.53–1.87) * | <0.001 |
Female sex; % (n) | 45.0 (229) | 51.2 (196) | 0.065 | ||
Comorbidities; % (n) | |||||
Previous stroke or TIA | 20.6 (105) | 30.0 (115) | 0.002 | 1.16 (0.92–1.46) | 0.210 |
Atrial fibrillation | 21.8 (111) | 41.0 (157) | <0.001 | 1.08 (0.85–1.37) | 0.523 |
Diabetes | 23.0 (117) | 36.0 (138) | <0.001 | 1.19 (0.96–1.48) | 0.108 |
Hypertension | 70.1 (357) | 76.5 (293) | 0.079 | ||
Coronary artery disease | 16.1 (82) | 30.0 (115) | <0.001 | 1.26 (0.99–1.60) | 0.053 |
Peripheral artery disease | 3.5 (18) | 10.2 (39) | <0.001 | 1.91 (1.35-2.71) | <0.001 |
Chronic heart failure | 11.8 (60) | 25.3 (97) | <0.001 | 1.13 (0.87–1.45) | 0.361 |
Chronic inflammatory airway disease | 5.9 (30) | 10.4 (40) | 0.010 | 1.43 (1.02–2.00) | 0.036 |
Antithrombotic medication prior to admission; % (n) | |||||
None | 70.1 (357) | 59.4 (227) | |||
Antiplatelets | 24.0 (122) | 36.1 (138) | <0.001 | 1.18 (0.94–1.48) | 0.164 |
Anticoagulation INR < 2 | 2.8 (14) | 2.4 (9) | 0.786 | 0.94 (0.47–1.86) | 0.858 |
Anticoagulation INR ≥ 2† | 3.1 (16) | 2.1 (8) | 0.512 | 0.59 (0.29–1.12) | 0.153 |
NIHSS$ on admission (per point); median (IQR) | 3.0 (1–7) | 7.0 (3–13) | <0.001 | 1.08 (1.06–1.10) | <0.001 |
Thrombolysis; % (n) | 5.9 (30) | 8.1 (31) | 0.034 | 0.922 | |